Merck KGaA, Pfizer's Javelin Phase 3 Trial Missed Primary Endpoints
19 Novembre 2018 - 2:20PM
Dow Jones News
By Chris Wack
Merck KGaA and Pfizer Inc. (PFE) said Monday the Javelin
clinical trial evaluating an ovarian cancer drug failed to meet its
primary endpoint.
The Phase III Javelin Ovarian 200 trial evaluated avelumab alone
or in combination with pegylated liposomal doxorubicin, or PLD,
compared with PLD. The companies said the trial didn't meet its
targets for overall survival or progression-free survival in
patients with platinum-resistant or -refractory ovarian cancer.
According to the companies, no new safety signals were observed
for avelumab alone or in combination, and the safety profile for
avelumab in this trial was consistent with that observed in the
overall Javelin clinical development program.
The study involved 566 women with ovarian cancer. The companies
said the study results would continue to be analyzed.
Shares of Merck KGaA were down 0.7% to EUR96.94 on the Frankfurt
stock exchange, and shares of Pfizer were untraded at $43.51
premarket.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
November 19, 2018 08:05 ET (13:05 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Pfizer (NYSE:PFE)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024
